化疗对非小细胞肺癌患者外周血中CD8+CD28-T细胞表达的影响

doi:10.3760/cma.j.issn.1673-422X.2016.05.004

摘要/Abstract

摘要： 目的观察非小细胞肺癌（NSCLC）患者外周血中CD8＋CD28-T细胞的表达水平，研究化疗对CD8＋CD28-T细胞表达的影响及意义。方法采用流式细胞仪检测70例初治NSCLC患者外周血CD8＋CD28-T细胞表达水平，以60例健康体检者作为对照，分析CD8＋CD28-T细胞与肺癌生物学及临床特征间的关系。观察30例NSCLC患者在给予长春瑞滨联合顺铂(NP)、吉西他滨联合顺铂(GP)两方案前后CD8＋CD28-T细胞表达的变化情况。结果NSCLC患者CD8＋CD28-T细胞的表达率为(59.003±15.329)%，明显高于健康对照组(41.036±15.435)%，差异有统计学意义(t=35.904，P=0.001)。CD8＋CD28-T细胞的表达与性别(F=1.374，P=0.697)、病理类型(F=0.779，P=0.509)及临床分期(F=0.070，P=0.933)无关，与年龄(F=15.038，P=0.001)有关。NP组化疗前后的CD8＋CD28-T细胞的表达率分别为(58.793±12.510)%和(55.293±14.637)%，差异有统计学意义(t=2.017，P=0.044)。GP组化疗前后的CD8＋CD28-T细胞的表达率分别为(60.700±16.401)%和(54.127±13.924)%，差异有统计学意义(t=3.007，P=0.009)。结论CD8＋CD28-T细胞在NSCLC患者外周血中高表达，化疗可下调CD8＋CD28-T细胞的表达，为探讨NSCLC化疗联合免疫治疗提供了新的参考。

关键词: 癌, 非小细胞肺, 药物疗法, CD8阳性T淋巴细胞

Abstract: ObjectiveTo observe the expression of CD8＋CD28-T cells in the peripheral blood of nonsmallcell lung cancer (NSCLC) patients, and to investigate the effect of chemotherapy on CD8＋CD28-T cells expression and its clinical significance. MethodsFlow cytometry was used to evaluate the level of CD8＋CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls. The association between CD8＋CD28-T cells and the clinical features was analyzed. We also investigated the changes of CD8＋CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine, cisplatin) and NP (navelbine, cisplatin). ResultsThe proportion of CD8＋CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003%±15.329% vs. 41.036%±15.435%, t=35.904, P=0.001). No correlation was found between CD8＋CD28-T cells expression and the gender (F=1.374, P=0.697), pathological pattern (F=0.779, P=0.509) and clinical stage (F=0.070, P=0.933). But CD8＋CD28-T cells expression was correlated with the age (F=15.038, P=0.001). The level of CD8＋CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293%±14.637% vs. 58.793%±12.510%, t=2.017, P=0.044). And the level of CD8＋CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127%±13.924% vs. 60.700%±16.401%, t=3.007, P=0.009). ConclusionCD8＋CD28-T cells express highly in NSCLC patients peripheral blood. Chemotherapy downregulates CD8＋CD28-T cells expression, which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients.

Key words: Carcinoma, nonsmallcell lung, Drug therapy, CD8positive Tlymphocytes

梁冠中,王艳峰,韩福才. 化疗对非小细胞肺癌患者外周血中CD8+CD28-T细胞表达的影响[J]. 国际肿瘤学杂志, 2016, 43(5): 335-339.

Liang Guanzhong, Wang Yanfeng, Han Fucai. Effect of chemotherapy on the expression of CD8+CD28-T cells in peripheral blood of nonsmallcell lung cancer patients[J]. Journal of International Oncology, 2016, 43(5): 335-339.

参考文献

［1］ Wang HY, Wang RF. Regulatory T cells and cancer［J］. Curr Opin Immunol, 2007, 19(2): 217-223. ［2］曹雪涛. 免疫学前沿进展［M］ . 北京: 人民卫生出版社, 2009: 365-387. ［3］ Liu Z, Tugulea S, Cortesini R, et al. Specific suppression of T helper alloreactivity by alloMHC class Ⅰrestricted CD8+CD28-T cells［J］. Int Immunol, 1998, 10(6): 775-783. ［4］ Yan X, Zhao X, Jiao S, et al. Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2012, 15(3): 164-171. DOI: 10.3779/j.issn.10093419.2012.03.06. ［5］ Riha P, Rudd CE. CD28 cosignaling in the adaptive immune response［J］. Self Nonself, 2010, 1(3): 231-240. DOI: 10.4161/self.1.3.12968. ［6］ Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers［J］. J Immunol, 2007, 179(7): 4323-4334. ［7］ Batliwalla FM, Rufer N, Lansdorp PM, et al. Oligoclonal expansions in the CD8(+)CD28(－) T cells largely explain the shorter telomeres detected in this subset: analysis by flow FISH［J］. Hum Immunol, 2000, 61(10): 951-958. ［8］ Li J, Liu Z, Jiang S, et al. T suppressor lymphocytes inhibit NFkappa Bmediated transcription of CD86 gene in APC［J］. J Immunol, 1999, 163(12): 6386-6392. ［9］ Karagz B, Bilgi O, Gümüs M, et al. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients［J］. Med Oncol, 2010, 27(1): 29-33. DOI: 10.1007/s1203200891659. ［10］ Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma［J］. Hum Immunol, 2006, 67(1/2): 1-12. DOI: 10.1016/j.humimm.2005.11.005. ［11］ Filaci G, SuciuFoca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity?［J］. Autoimmun Rev, 2002, 1(5): 279283. ［12］ Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation［J］. J Clin Invest, 2004, 114(9): 1198-1208. DOI: 10.1172/JCI23411. ［13］ Chen X, Priatel JJ, Chow MT, et al. Preferential development of CD4 and CD8 T regulatory cells in RasGRP1deficient mice［J］. J Immunol, 2008, 180(9): 5973-5982. ［14］薛利军, 尹路, 陈春球, 等. 利用RNA干扰诱导产生的CD8+CD28-抑制性T淋巴细胞的免疫学特性［J］. 中华器官移植杂志, 2009, 30(5): 295-299. DOI: 10.3760/cma.j.issn.02541785.2009.05.012. ［15］储以微, 刘荣军, 张镭, 等. 肺癌患者化疗前后免疫细胞格局的改变及其临床意义［J］. 中国肿瘤生物治疗杂志, 2006, 13(4): 253-256. DOI: 10.3872/j.issn.1007385X.2006.04.004. ［16］ Wang LX, Li R, Yang G, et al. Interleukin7dependent expansion and persistence of melanomaspecific T cells in lymphodepleted mice lead to tumor regression and editing［J］. Cancer Res, 2005, 65(22): 10569-10577. DOI: 10.1158/00085472.CAN052117. ［17］ Zhang TQ, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer［J］. Cancer Immunol Immunother, 2009, 58(4): 475-492. DOI: 10.1007/s002620080598y. ［18］ Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients［J］. Cancer Immunol Immunother, 2007, 56(5): 641-648. DOI: 10.1007/s0026200602258. ［19］ Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine［J］. Blood, 2005, 106(6): 2018-2025. DOI: 10.1182/blood2005020642. ［20］ Liu Q, Zheng H, Chen X, et al. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(－) regulatory T cells［J］. Cell Mol Immunol, 2015, 12(6): 708-718. DOI: 10.1038/cmi.2014.118.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.